[1] Yap, D.Y. and K.N. Lai, Pathogenesis of renal disease in systemic lupus erythematosus--the role of autoantibodies and lymphocytes subset abnormalities. Int J Mol Sci, 2015. 16(4): p. 7917-31.
[2] Chen, M., M.R. Daha, and C.G. Kallenberg, The complement system in systemic autoimmune disease. J Autoimmun, 2010. 34(3): p. J276-86.
[3] Couture, J. and E.D. Silverman, Update on the pathogenesis and treatment of childhood-onset systemic lupus erythematosus. Curr Opin Rheumatol, 2016. 28(5): p. 488-96.
[4] Lipsky, P.E., Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol, 2001. 2(9): p. 764-6.
[5] Mok, C.C. and C.S. Lau, Pathogenesis of systemic lupus erythematosus. J Clin Pathol, 2003. 56(7): p. 481-90.
[6] Edelbauer, M., et al., Markers of childhood lupus nephritis indicating disease activity. Pediatr Nephrol, 2011. 26(3): p. 401-10.
[7] Lukawska, E., M. Polcyn-Adamczak, and Z.I. Niemir, The role of the alternative pathway of complement activation in glomerular diseases. Clin Exp Med, 2018. 18(3): p. 297-318.
[8] Dumestre-Perard, C., et al., Antibodies targeting circulating protective molecules in lupus nephritis: Interest as serological biomarkers. Autoimmun Rev, 2018. 17(9): p. 890-899.
[9] He, J. and Z. Li, An era of biological treatment in systemic lupus erythematosus. Clin Rheumatol, 2018. 37(1): p. 1-3.
[10] Gatto, M., et al., Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis. J Autoimmun, 2016. 74: p. 94-105.
[11] Wakamiya, N., et al., [New Complement Therapeutics in Complement-Related Diseases]. Brain Nerve, 2019. 71(6): p. 555-564.
[12] Barilla-Labarca, M.L., K. Toder, and R. Furie, Targeting the complement system in systemic lupus erythematosus and other diseases. Clin Immunol, 2013. 148(3): p. 313-21.
[13] Benamu, E. and J.G. Montoya, Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis, 2016. 29(4): p. 319-29.
[14] Qiao, Q., et al., A novel CRIg-targeted complement inhibitor protects cells from complement damage. FASEB J, 2014. 28(11): p. 4986-99.
[15] Trouw, L.A., M.C. Pickering, and A.M. Blom, The complement system as a potential therapeutic target in rheumatic disease. Nat Rev Rheumatol, 2017. 13(9): p. 538-547.
[16] Pouw, R.B., et al., Of mice and men: The factor H protein family and complement regulation. Mol Immunol, 2015. 67(1): p. 12-20.
[17] Sada, K.E. and H. Makino, Usefulness of ISN/RPS classification of lupus nephritis. J Korean Med Sci, 2009. 24 Suppl: p. S7-10.
[18] Anders, H.J. and A.B. Fogo, Immunopathology of lupus nephritis. Semin Immunopathol, 2014. 36(4): p. 443-59.
[19] Lorenz, G., J. Desai, and H.J. Anders, Lupus nephritis: update on mechanisms of systemic autoimmunity and kidney immunopathology. Curr Opin Nephrol Hypertens, 2014. 23(3): p. 211-7.
[20] Sato, N., et al., Significance of glomerular activation of the alternative pathway and lectin pathway in lupus nephritis. Lupus, 2011. 20(13): p. 1378-86.
[21] Wang, Y., et al., Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci U S A, 1996. 93(16): p. 8563-8.
[22] Sciascia, S., et al., Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. Rheumatol Int, 2017. 37(8): p. 1249-1255.
[23] Rovin, B.H. and S.V. Parikh, Lupus nephritis: the evolving role of novel therapeutics. Am J Kidney Dis, 2014. 63(4): p. 677-90.
[24] Gackler, A., et al., Failure of first meningococcal vaccination in patients with atypical haemolytic uraemic syndrome treated with eculizumab. Nephrol Dial Transplant, 2018.
[25] Lieberman, L.A., et al., Complement receptor of the immunoglobulin superfamily reduces murine lupus nephritis and cutaneous disease. Clin Immunol, 2015. 160(2): p. 286-91.
[26] He, J.Q., C. Wiesmann, and M. van Lookeren Campagne, A role of macrophage complement receptor CRIg in immune clearance and inflammation. Mol Immunol, 2008. 45(16): p. 4041-7.
[27] Sekine, H., et al., The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. Arthritis Rheum, 2011. 63(4): p. 1076-85.
[28] Coppo, R., et al., Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr Nephrol, 2015. 30(1): p. 167-72.